Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Midcap & small cap buck trend
Mon, 23 Jun 01:30 pm

Indian share markets slipped deeper in the red in the post-noon trading session. Sectoral indices are trading mixed with FMCG and IT stocks being the biggest losers whereas auto and metal stocks are trading in the green.

BSE-Sensex is down 137 points and NSE-Nifty is trading 47 points down. Both BSE Mid Cap and BSE Small Cap indices are trading up by 0.2%. The rupee is trading at 59.04 to the US dollar.

Most of the domestic pharma stocks are trading in the green with Indoco Remedies and Dishman Pharma being the major gainers whereas Orchid Chemicals and Biocon are trading in the red. As per a leading financial daily, pharmaceutical companies will have to gear up for a stricter price regime as the government is contemplating to bring legislation that will cover all kinds of medicines including patented, imported and even non-scheduled drugs. The legislation will consider pricing models across the US, European Union, China and 14 countries from Organization of Economic Co-operation and Development (OECD). The National Pharmaceutical Pricing Authority (NPPA) has commenced work in this regard. NPPA plans to come up with the first draft of the legislation by the end of FY15. Presently around 30% of Rs 790 bn domestic pharmaceutical market is regulated with the prices of 348 essential medicines capped at the average price of all drugs in a particular segment having more than 1% market share. The prices of these drugs can be raised annually in line with the Wholesale price Index whereas the prices of all the other drugs can be raised by upto 10% annually.

Auto stocks are trading mixed. Gains are being led by Maharashtra Scooters and Hero MotoCorp, while Eicher Motors is trading weak. As per a leading business daily, Bajaj Auto is planning to begin retail sales of quadricycles by this October. This comes after the Ministry of Road & Transport confirmed that quadricycles could ply on the Indian roads by October. Bajaj Auto doesn't want to lose any time and will test the Bajaj RE60. The company has developed 60,000 p.a. capacity of RE60 at its Waluj plant in Maharashtra. Further the company has also developed left-hand version of quadricycles for export markets. However, in terms of financials the impact of quadricycles won't be that significant for at least next two years at both top line as well as bottom line. Bajaj Auto is trading firm by 0.7% on BSE today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Midcap & small cap buck trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.